TYMS and breast carcinoma: Our modeling analysis comparing the affinity of curcumin with that of LY231514 (pemetrexed), a multitargeted antifolate used in the treatment of advanced breast cancer, indicated a superior affinity of curcumin over LY231514 towards TS cofactor-binding site.